FOR IMMEDIATE RELEASE
Adicet Bio Named as One of FierceBiotech’s
Menlo Park, CA (September 19, 2016) – Adicet Bio, Inc. today announced that it has been named by FierceBiotech as one of 2016's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
“We are honored to be selected to the “
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at https://pages.questexweb.com/FierceBiotech-Newsletter-Signup.html?_ga=1.2394681.800155757.1473173899.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, preclinical stage biotechnology company that is engaged in the development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT). Adicet’s wholly owned subsidiary, Applied Immune Technologies, Ltd. is developing immunotherapies directed to the disease-specific peptide-MHC complexes associated with different disease indications.
# # #
Aya Jakobovits, Ph.D.
President and Chief Executive Officer
Adicet Bio, Inc.